CHA Biotech said on the 26th that its U.S. subsidiary Matica Biotechnology signed a contract for contract development and manufacturing (CDMO) of an adenovirus therapy with a North American medical research institution. Adenovirus is called "sleepy-eye cold" among infants and toddlers and causes high fever and sore throat.
Matica Biotechnology supports all stages from early development to production of the adenovirus therapy. It provides services such as cell line establishment, process development, and quality testing. The contract amount will remain confidential by mutual agreement.
Matica Biotechnology was established by CHA Biotech in 2022 in the United States to enter the contract manufacturing market for cell and gene therapies. Cell and gene therapies are next-generation medicines that fundamentally cure diseases by modifying a patient's cells or genes.
Matica Biotechnology has its own platform related to adenovirus. Paul Kim, CEO of Matica Biotechnology, said, "We will ensure that the therapy our client is developing can enter the clinical stage."